Insulin degludec improves health-related quality of life (SF-36 A )...
Insulin degludec improves health-related quality of life compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Positive Phase III Results Reported for Investigational Insulin
In a phase III study, 23% fewer diabetic subjects treated with an investigational insulin product experienced nocturnal hypoglycemia compared with subjects treated with Lantus .
Obesity Drug Highlights Novo Nordisk Presentation
BagsvA rd, Denmark, 3 December 2013 - Today at its Capital Markets Day, Novo Nordisk will present an update on its commercial performance and key development projects, which are expected to drive long-term growth.
Applied Clinical Trials
Sanofi Announces New Phase 3 Results for Investigational New Insulin U300
These results were presented today at the International Diabetes Federation 2013 World Diabetes Congress in .
New data backs promise of long-acting Sanofi insulin
An improved version of Sanofi's diabetes drug Lantus is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed on Tuesday.
Adocia Announces The Initiation Of A Clinical Trial On Its...
Adocia , a biotechnology company specializing in the development of 'best-in-class' medicines from already approved therapeutic proteins, announces today that it has launched the first clinical trial of its innovative formulation combining insulin Glargine , Sanofi), the gold-standard of long acting insulin, with a fast-acting insulin analog, ... (more)